Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

C4 Therapeutics (CCCC) Gross Profit: 2019-2024

Historic Gross Profit for C4 Therapeutics (CCCC) over the last 6 years, with Dec 2024 value amounting to $35.6 million.

  • C4 Therapeutics' Gross Profit fell 26.90% to $11.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $30.1 million, marking a year-over-year decrease of 10.57%. This contributed to the annual value of $35.6 million for FY2024, which is 71.44% up from last year.
  • C4 Therapeutics' Gross Profit amounted to $35.6 million in FY2024, which was up 71.44% from $20.8 million recorded in FY2023.
  • Over the past 5 years, C4 Therapeutics' Gross Profit peaked at $45.8 million during FY2021, and registered a low of $20.8 million during FY2023.
  • In the last 3 years, C4 Therapeutics' Gross Profit had a median value of $31.1 million in 2022 and averaged $29.1 million.
  • In the last 5 years, C4 Therapeutics' Gross Profit crashed by 33.25% in 2023 and then soared by 71.44% in 2024.
  • Over the past 5 years, C4 Therapeutics' Gross Profit (Yearly) stood at $33.2 million in 2020, then spiked by 37.93% to $45.8 million in 2021, then tumbled by 32.08% to $31.1 million in 2022, then crashed by 33.25% to $20.8 million in 2023, then surged by 71.44% to $35.6 million in 2024.